Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVMED-80 for Keratoconus Progression
NCT05241145Phase 2Completed
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of copper sulfate in keratoconus and corneal ectasia (3 arms). Primary endpoints: Mean Maximum Central Keratometry at 26 weeks, Treatment-Emergent Adverse Events at 26 weeks and 1 more. Started Feb 2019; status: completed.
02
Drugs
copper sulfate
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT05241145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241145.